Heart resynchronization illustrated with precise electrical pathways.

Heart Pacing Revolution: Can MultiPoint Pacing Improve CRT Outcomes?

Mira Elwood monogram
Mira Elwood in Health & Wellness October 2026 • 3 min read.

"Discover how a new clinical trial is exploring MultiPoint Pacing (MPP) therapy to enhance cardiac resynchronization for heart failure patients."


Heart failure remains a significant health challenge, with a substantial portion of patients not responding adequately to cardiac resynchronization therapy (CRT). CRT aims to improve the heart's efficiency by coordinating the contractions of the left and right ventricles. However, nearly 40% of patients don't experience the full benefits, leading researchers to explore innovative approaches.

MultiPoint Pacing (MPP) has emerged as a promising alternative. This technique involves pacing the heart at multiple points, potentially leading to more coordinated and effective contractions. Early studies suggest that MPP can improve outcomes for some patients, but more rigorous research is needed to confirm these findings.

The MORE-CRT MPP PHASE II trial is designed to provide that evidence. This randomized, multi-center study aims to assess the safety and efficacy of MPP in patients who have not responded to traditional CRT. By evaluating MPP's impact on heart function and overall health, this trial could revolutionize heart failure treatment.

AI Search Multiple angles on this topic

CRT Use in U.S. Hospitals

A serial cross-sectional study using the National Inpatient Sample identified 311,086 admissions associated with CRT implantation from 2006 through 2012. CRT-D was the most common device type, accounting for 86.1% of those admissions. Among patients aged 75 or older with five or more Elixhauser comorbidities, CRT-D accounted for 75.5% of devices.

From Pacemaker Origins to Modern CRT

A 2007 overview of CRT history notes that pacemakers were originally developed to improve cardiac function in people with heart failure. A 2014 review describes CRT’s evolution from “bench to bedside” and the challenge of making the therapy available to more eligible patients. A 2024 review characterizes CRT as a beneficial, disease-modifying treatment for appropriately selected patients with heart failure.

What is MultiPoint Pacing and Why is it Important?

Heart resynchronization illustrated with precise electrical pathways.

Traditional CRT typically involves pacing at one or two points in the heart's left ventricle. In contrast, MPP uses a special lead with multiple electrodes to pace at several locations simultaneously. This multi-point approach may:

This innovative approach seeks to address the limitations of traditional CRT by:

  • Achieve more synchronized ventricular contractions.
  • Increase the amount of heart tissue activated during pacing.
  • Improve the heart's overall efficiency.
AI Search Multiple angles on this topic

Recent CRT Reviews

A Nature subject listing dated September 29, 2026, points readers to recent research on CRT in heart failure management. A review dated October 14, 2024, examines ongoing challenges, evolving indications, and modern advances involving other pacing modalities to achieve CRT. Together, these listings show attention to both CRT research and changes in pacing approaches.

Limits of the MORE-CRT MPP Evidence

The MORE-CRT MPP randomized study did not find a significant difference between multipoint pacing (MPP) and biventricular pacing (BIVP) in the rate of CRT non-response when response was assessed by left-ventricular end-systolic volume reduction greater than 15%. The trial sponsor closed the study early in 2020 after a prespecified interim analysis indicated a low probability of meeting its primary endpoint. These findings caution against assuming that MPP reliably improves outcomes for all CRT non-responders.

MPP Trial Safety Result

The MultiPoint Pacing Trial assessed the safety and efficacy of multipoint pacing in CRT. Its reported primary safety endpoint was met, with freedom from system-related complications of 93.2%. The available result does not provide a comparative efficacy figure, so it cannot establish from this information alone whether MPP outperformed standard biventricular pacing.

MPP's potential to enhance cardiac function has garnered significant attention, leading to the development of the MORE-CRT MPP PHASE II trial to rigorously evaluate its benefits.

The Future of Heart Failure Treatment

The MORE-CRT MPP PHASE II trial represents a crucial step in advancing heart failure therapy. By providing robust evidence on the benefits of MPP, this study could pave the way for a new standard of care, offering hope to the many patients who do not respond to traditional CRT. The results of this trial are eagerly anticipated and may transform the landscape of cardiac pacing.

AI Search Multiple angles on this topic

Research to Guide Future Care

A comprehensive review published January 29, 2025, aims to present recent findings from CRT clinical trials and systematic reviews. Its stated purpose is to highlight evidence likely to guide future directions in patient care. The source does not specify which particular future strategies will prove effective.

Challenges in CRT Practice

A review titled “Evolving Indications, Challenges and Advances in Cardiac Resynchronization Therapy for Heart Failure” focuses on challenges and changing indications in CRT. The supplied source excerpt identifies research topics through a unique fingerprint but does not describe specific systemic barriers or solutions. It therefore supports the existence of ongoing discussion about CRT challenges, but not conclusions about their scale or causes.

Care Pathways and Real-World Outcomes

A 2022 study set out to evaluate a routine in-hospital CRT program that included comprehensive heart-failure evaluation and systematic echo-guided optimization. A 2021 real-world cohort study used preimplant heart-failure hospitalization data to examine CRT’s postimplant impact on hospitalization frequency and associated costs. It also examined whether SyncAV CRT added value beyond CRT overall, but the supplied excerpts do not report the study’s results.

What the MPP results suggest-and do not establish

The reports point to possible gains on some measures, including ejection fraction and functional improvement, but they do not show a consistent advantage across every comparison. Differences in the measure and comparison matter when interpreting claims that MPP is better overall.[1] [2] [3]

An analysis of trial data was explicitly described as exploratory and hypothesis-generating. Its findings therefore suggest a possibility rather than proving that MPP benefits people who remain unresponsive despite standard biventricular pacing.[4]

How MPP compares across pacing reports

A pooled comparison reported greater functional improvement and higher change in LV dP/dtmax with MPP than with biventricular pacing. Another pooled analysis also found a greater ejection-fraction increase, while a separate comparison found no significant difference on response measures.[1] [2] [3]

Practical trade-offs also appear in the evidence: MPP was associated with reduced battery longevity, and neither it nor echo-guided optimization was consistently shown superior to conventional CRT in large multicenter studies. A scar-based predictive value was derived and tested in the same cohort, so its authors called for prospective corroboration; pacing near scar also has a proposed mechanism for triggering ventricular tachycardia.[5] [6] [7]

What remains unresolved about MPP

  • Can the exploratory findings in people unresponsive to standard pacing be confirmed in prospective testing, and would results differ according to pacing-vector choice or scar-related characteristics?[4] [6] [8]

Sources

  1. Cardiac resynchronization therapy with multipoint pacing via quadripolar lead versus traditional biventricular pacing: A systematic review and meta-analysis of clinical studies on hemodynamic, clinica (pmc.ncbi.nlm.nih.gov)
  2. Efficacy of multipoint versus conventional biventricular pacing in CRT: systematic review and meta-analysis of randomized trials (pmc.ncbi.nlm.nih.gov)
  3. Multipoint pacing for cardiac resynchronisation therapy in patients with heart failure: A systematic review and meta-analysis (pmc.ncbi.nlm.nih.gov)
  4. Multipoint pacing is associated with improved prognosis and cardiac resynchronization therapy response: MORE-CRT MPP randomized study secondary analyses (pmc.ncbi.nlm.nih.gov)
  5. Optimization of CRT programming using non‐invasive electrocardiographic imaging to assess the acute electrical effects of multipoint pacing (pmc.ncbi.nlm.nih.gov)
  6. Left ventricular scar and the acute hemodynamic effects of multivein and multipolar pacing in cardiac resynchronization (pmc.ncbi.nlm.nih.gov)
  7. Pacing in proximity to scar during cardiac resynchronization therapy increases local dispersion of repolarization and susceptibility to ventricular arrhythmogenesis (pmc.ncbi.nlm.nih.gov)
  8. Vector Selection of a Quadripolar Left Ventricular Pacing Lead Affects Acute Hemodynamic Response to Cardiac Resynchronization Therapy: A Randomized Cross-Over Trial (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is MultiPoint Pacing (MPP), and how does it differ from traditional methods?

MultiPoint Pacing (MPP) is a technique used to pace the heart at multiple points simultaneously, using a specialized lead with multiple electrodes. This contrasts with traditional Cardiac Resynchronization Therapy (CRT), which typically paces at only one or two points in the left ventricle. MPP aims to achieve more synchronized ventricular contractions, increase the amount of heart tissue activated during pacing, and improve the heart's overall efficiency. This is particularly important because a significant number of heart failure patients do not respond adequately to traditional CRT. By addressing the limitations of traditional CRT, MPP offers the potential to improve outcomes for these patients.

2

What is the purpose of the MORE-CRT MPP PHASE II trial, and why is it so important?

The MORE-CRT MPP PHASE II trial is a randomized, multi-center study designed to assess the safety and efficacy of MultiPoint Pacing (MPP) in patients who have not responded to traditional Cardiac Resynchronization Therapy (CRT). The goal is to rigorously evaluate MPP's impact on heart function and overall health. The trial is significant because it represents a crucial step in determining whether MPP can become a new standard of care for heart failure patients who do not benefit from traditional CRT. By providing robust evidence, the trial could transform the landscape of cardiac pacing and offer hope to a substantial portion of patients.

3

Could you explain what Cardiac Resynchronization Therapy (CRT) is and why it's used?

Cardiac Resynchronization Therapy (CRT) is a treatment that aims to improve the heart's efficiency by coordinating the contractions of the left and right ventricles. This coordination is crucial because, in heart failure, the ventricles often contract in a disorganized manner, reducing the heart's ability to pump blood effectively. CRT typically involves pacing at one or two points in the left ventricle to synchronize these contractions. However, a significant percentage of patients do not respond fully to traditional CRT, which is why alternative approaches like MultiPoint Pacing (MPP) are being explored.

4

How does MultiPoint Pacing (MPP) enhance cardiac function, and what are the potential benefits?

MultiPoint Pacing (MPP) seeks to enhance cardiac function by pacing the heart at multiple locations simultaneously. This approach is designed to achieve more synchronized ventricular contractions and increase the amount of heart tissue activated during pacing, ultimately improving the heart's overall efficiency. The potential benefits of MPP include better coordination of the heart's contractions, more effective pumping of blood, and improved outcomes for patients who do not respond adequately to traditional Cardiac Resynchronization Therapy (CRT). The MORE-CRT MPP PHASE II trial aims to rigorously evaluate these potential benefits.

5

What could be the implications if the MORE-CRT MPP PHASE II trial is successful?

If the MORE-CRT MPP PHASE II trial demonstrates the safety and efficacy of MultiPoint Pacing (MPP), it could revolutionize heart failure treatment by establishing MPP as a new standard of care for patients who do not respond to traditional Cardiac Resynchronization Therapy (CRT). This would offer hope to a significant portion of heart failure patients who currently do not experience the full benefits of CRT. The trial's success could lead to wider adoption of MPP, improved patient outcomes, and a transformation in the approach to cardiac pacing.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.